Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions

Last updated: July 30, 2009
Sponsor: University of Rochester
Overall Status: Completed

Phase

4

Condition

Coronary Artery Disease

Vascular Diseases

Thrombosis

Treatment

N/A

Clinical Study ID

NCT00481741
RSRB00018198
  • Ages > 18
  • All Genders

Study Summary

We seek to determine if the use of the SafeSeal(TM) topical hemostasis patch is associated with reductions in time to hemostasis and time to ambulation compared to standard manual compression after arterial sheath removal following percutaneous coronary and peripheral intervention. We further seek to assess the safety of the SafeSeal patch compared to manual compression.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patient ≥ 18 years old

  2. Coronary or peripheral vascular intervention

  3. 6 French arterial sheath used

  4. Overnight hospitalization following procedure

Exclusion

Exclusion Criteria:

  1. Hematoma or persistent bleeding around the vascular sheath

  2. Previous AV fistula or pseudoaneurysm in the ipsilateral femoral artery

  3. History of bleeding diathesis or coagulopathy

  4. Hemoglobin level < 9 g/dl

  5. Inability to ambulate at baseline

  6. Known allergy to any of the materials used in the SafeSeal

  7. Female patients known to be pregnant or lactating

  8. Evidence of ongoing systemic or cutaneous infection

  9. Uncontrolled blood pressure following PCI (systolic blood pressure > 180 or diastolicblood pressure >110)

  10. Current enrolment in another ongoing investigational drug/device trial.

Study Design

Total Participants: 150
Study Start date:
May 01, 2007
Estimated Completion Date:
December 31, 2007

Study Description

A variety of topical hemostasis pads containing procoagulant materials are currently available to accelerate hemostasis after removal of the arterial introducer sheath following coronary and peripheral arterial angioplasty procedures. The effectiveness and safety of these pads, however, remains poorly understood. A total of 150 patients undergoing coronary or peripheral vascular angioplasty through a 6 French arterial sheath will be randomized to sheath removal using manual compression alone or manual compression combined with use of the SafeSeal(TM) hemostasis patch. Sheaths will be removed at an activated clotting time (ACT) of <250 seconds, and patients will be kept at bedrest for 2 hours after hemostasis is achieved. The primary endpoint will be time to hemostasis. Secondary endpoints witll include time to ambulation and frequency of bleeding complications.

Connect with a study center

  • University of Rochester Medical Center

    Rochester, New York 14642
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.